109 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
7 May 24
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
4:05pm
due to a decrease in employee related costs, partially offset by an increase in third party expenses. Total R&D stock-based compensation expense
PRE 14A
ALGS
Aligos Therapeutics Inc
16 Apr 24
Preliminary proxy
5:27pm
Units
Reserved
for Future
Issuance
Pursuant
to New
Grants
Under the
2020 Incentive
Award Plan
Reserved
for Future
Issuance
Pursuant
to 2020
Employee …
Issuance
Pursuant
to 2020
Employee
Stock
Purchase
Plan
Pre-Reverse Stock Split
Post-Reverse Stock Split 1 for 5
Post-Reverse Stock Split 1 for 15
S-8
EX-5.1
ALGS
Aligos Therapeutics Inc
12 Mar 24
Registration of securities for employees
4:51pm
of the Company, par value $0.0001 per share (the “Shares”), issuable under the Company’s 2020 Incentive Award Plan (the “2020 Plan”) and 2020 Employee Stock
S-8
EX-23.2
b58fgr gddppvprf5l
12 Mar 24
Registration of securities for employees
4:51pm
S-8
zgskha5x
12 Mar 24
Registration of securities for employees
4:51pm
S-8
pp22f
12 Mar 24
Registration of securities for employees
4:51pm
SC TO-I
EX-99
53872q13uqn136z2wj
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
k78tk6m z9gvkhy62no
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
pyqce7qufjc 94
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
h9cdwq3s7qkw
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
ntruvor39qv 4r
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
ftk03eos
30 Jan 24
Issuer tender offer statement
7:04am
SC TO-I
EX-99
0zhch5kmwx8dgmf 2f
30 Jan 24
Issuer tender offer statement
7:04am